Supriya Lifescience Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company reported that it has not utilized any working capital limits in the last 9 months except for letters of credit and bank guarantees, indicating stable liquidity. - Capex plans include approximately INR 15 crores for the remainder of FY26 (primarily maintenance and small projects), with no immediate mention of the need for additional funding. - The company plans significant capex at the Patalganga site starting next year, potentially around INR 40-50 crores initially, but funding sources or fundraising plans for this are not discussed. - Overall, the management has not indicated any intention to raise new equity or debt in the near term based on the available information.

- Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility. - Remaining FY26 capex expected around INR 15 crores for maintenance and small projects like Riboflavin block and formulation plant needs. - Planned ground-breaking for Patalganga site utilities block in coming year with initial INR 40-50 crores investment. - Future plan includes setting up either an API or formulation facility at Patalganga targeted around FY29. - Ambernath facility capex estimated between INR 140-160 crores; commercial revenue expected from Q4 FY26, EBITDA positive around Q3 FY27. - Isambe site blueprint finalization underway; site possession obtained after environmental clearance, with construction expected to start soon. - Strategic focus on capacity enhancements, new R&D facilities, and backward integration to support growth above 20%.

- Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. - Expectation to achieve INR1,000 crores revenue milestone in FY27 supported by: - Scale-up of existing product basket in regulated markets. - Launch of 3 to 4 new products per year, with new products contributing around 10% of revenue in 2-3 years. - Commercial revenue from the newly commissioned Ambernath finished formulation facility starting Q4 FY26, with full impact in FY27. - Backward integration is increasing, currently at 74%, expected to rise to 80-82% soon. - Long-term aim includes healthy growth via new products, contract manufacturing, and CDMO pipeline. - Certain large product volumes (e.g., cardiovascular product visibility of 250-300 tons) are expected to fully realize in FY27. - CDMO/CMO and new products combined are targeted to contribute 20% of revenues in medium term.

- Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products. - Revenue is expected to reach around INR1,000 crores in FY27, driven by core therapeutic segments and the Ambernath facility. - EBITDA margins are maintained between 33% to 35%. - Ambernath facility is expected to start commercial revenue in Q4 FY26, achieving EBITDA positivity around Q3 FY27. - New product launches (3-4 annually) are expected to contribute about 10% of revenues in 2-3 years. - Backward integration will increase from 74% to 80-82%, supporting margin sustainability. - The company plans to leverage CDMO/CMO growth as part of its strategy, contributing toward the 20% combined growth target with new products. - Strong order book visibility and export markets (LatAm, Europe) will support consistent growth.

- The company has good visibility on the order book for Q4 FY26, confident of achieving the revenue targets. - Supriya Lifescience is not quantifying the exact order book but confirms firm visibility and volume commitments from customers. - For the ATS-8 product for FY27, they have identified annual consumption for end users, with many in the signing stage of volume commitments. - Large contracts for CDMO/CMO are under discussion, with term sheets being signed; announcements expected in coming quarters. - Some shipments intended for late December were delayed due to holidays, causing spillover of business into Q4. - The company is confident in its ability to achieve approximately 20% annual revenue growth based on current order book and pipeline visibility.